Agilent Technologies recently gained FDA approval for its PD-L1 IHC 22C3 pharmDx, making it the only authorized companion diagnostic for certain ovarian, fallopian tube, or primary peritoneal carcinoma patients treated with KEYTRUDA. This marks the diagnostic’s seventh FDA-approved indication with KEYTRUDA. HSBC analyst Sidharth Sahoo initiated coverage with a Buy rating and a $180 price target, citing Agilent’s leadership in life sciences and diagnostics and its strong position for sustained growth.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Agilent Technologies, Inc. (A) Sparks Confidence With Latest Approvals
Agilent Technologies recently gained FDA approval for its PD-L1 IHC 22C3 pharmDx, making it the only authorized companion diagnostic for certain ovarian, fallopian tube, or primary peritoneal carcinoma patients treated with KEYTRUDA. This marks the diagnostic’s seventh FDA-approved indication with KEYTRUDA. HSBC analyst Sidharth Sahoo initiated coverage with a Buy rating and a $180 price target, citing Agilent’s leadership in life sciences and diagnostics and its strong position for sustained growth.